The Study of Yin-Chen-Hao-Tang Preventing and Treating Alcoholic Fatty Liver Disease through PPAR Signaling Pathway Based on Network Pharmacology and RNA-Seq Transcriptomics

Yi-Wei Zhu, Du Li, Ting-Jie Ye, Feng-Jun Qiu, Xiao-Ling Wang, Xiao-Feng Yan, Yan-Lin Lu, Wei Xu, Hua Li, and Xu-Dong Hu

Department of Biology, School of Basic Medical Science, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

Correspondence should be addressed to Xu-Dong Hu; huxudongsh@126.com

Received 25 September 2021; Revised 15 November 2021; Accepted 9 December 2021; Published 31 December 2021

Academic Editor: Lu sa Mota da Silva

Copyright © 2021 Yi-Wei Zhu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Alcoholic fatty liver disease (AFLD) is the first stage of the alcoholic liver disease course. Yin-Chen-Hao-Tang (YCHT) has a good clinical effect on the treatment of AFLD, but its molecular mechanism has not been elucidated. In this study, we tried to explore the molecular mechanism of YCHT in improving hepatocyte steatosis in AFLD mice through network pharmacology and RNA sequencing (RNA-Seq) transcriptomics. Methods. Network pharmacological methods were used to analyze the potential therapeutic signaling pathways and targets of YCHT on AFLD. Then, the AFLD mice model was induced and YCHT was administrated concurrently. Liver injury was measured by serum alanine aminotransferase (ALT) activity and liver tissue H&E staining, and liver steatosis was determined by serum triglyceride (TG) level and liver tissue Oil Red staining. The molecular mechanism of YCHT on prevention and treatment of mice AFLD was investigated according to the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of the differential expression genes data obtained by liver tissue RNA-Seq. Finally, ethanol-induced AFLD AML12 hepatocyte model was established, YCHT with or without PPARα agonist pemafibrate or PPARγ inhibitor GW9662 was administrated. Nile Red fluorescent staining was used to evaluate steatosis levels in AML12 hepatocytes, and qRT-PCR was used to detect PPARα and PPARγ gene expression. Results. The results of network pharmacology analysis showed that YCHT may exert its pharmacological effect on AFLD through 312 potential targets which are involved in many signaling pathways including the PPAR signaling pathway. AFLD mice experiments results showed that YCHT markedly decreased mice serum ALT activity and serum TG levels. YCHT also significantly improved alcohol-induced hepatic injury and steatosis in mice livers. Furthermore, KEGG pathway enrichment results of RNA-Seq showed that the PPAR signaling pathway should be the most relevant pathway of YCHT in the prevention and treatment of AFLD. AFLD hepatocyte model experiment results showed that YCHT could remarkably reduce hepatocyte steatosis through reducing PPARγ expression and increasing PPARα expression. Conclusions. Our study discovered that PPARγ and PPARα are the key targets and the PPAR signaling pathway is the main signaling pathway for YCHT to prevent and treat AFLD.

1. Introduction

Globally, in 2010, the number of deaths from alcohol-attributable liver cirrhosis was 493,300, and alcoholic cirrhosis deaths accounted for 47.9% of all liver cirrhosis deaths [1]. In developed regions such as North America and Europe, alcoholic liver disease is the leading cause of cirrhosis. In China, with the improvement of living standards and the change of lifestyle, the proportion of alcoholics in the population has increased year by year. The percentage of regular alcohol drinkers among the general adult population in different areas increased from 27.0% in 2000 to 66.2% in 2015. The 22.7% alcoholic liver disease (ALD) prevalence in 2000 was increased to 8.74% in 2015 [2]. Alcoholic fatty liver disease
(AFLD) is the first response of the liver to alcohol abuse, and it is the first stage in the progression of ALD; it can progress to steatohepatitis, fibrosis, and cirrhosis, leading to an increased probability of hepatic failure and death [3]. The prevention and treatment of AFLD are beneficial for blocking the progression of alcoholic liver disease. However, there is currently no specific drug for the therapy of AFLD.

The traditional Chinese medicine treatment of AFLD has achieved a good therapeutic effect. The classical prescription Yin-Chen-Hao-Tang (YCHT) has been used for the treatment of AFLD in clinic, and its curative effect is excellent [4, 5]. YCHT consists of Artemisia Scopariae Herba, Gardeniae Fructus, and Radix Rhei Et Rhizome. Studies showed that YCHT can effectively alleviate hepatic fibrosis and steatosis [6]. YCHT could also improve AFLD in rats due to its effect on antialcoholic hepatotoxicity and reducing liver fat deposition [7], and it could protect rats [8] and mice [9] from acute alcoholic liver injury by scavenging oxygen free radicals and reducing lipid peroxidation. But the molecular mechanism underlying was still unknown.

In this study, we tried to elucidate the key signal pathways and main targets of YCHT in the prevention and treatment of AFLD through dry experiments (network pharmacological analysis) and wet experiments (AFLD mouse model and AFLD mouse hepatocyte model experiments).

2. Materials and Methods

2.1. Network Pharmacological Analysis of Therapeutic Pathways and Targets of Yin-Chen-Hao-Tang (YCHT) in the Prevention and Treatment of Alcoholic Fatty Liver Disease (AFLD). Firstly, the effective components and potential pharmacological targets of Artemisia Scopariae Herba, Gardeniae Fructus, and Radix Rhei Et Rhizome were obtained by TCMSP (https://tcmsp-e.com/) online database. Then, the total target set of YCHT was obtained by combining the target sets of these three herbs. Secondly, we got the disease-related target set of alcoholic fatty liver disease (AFLD) through searching for the keyword “alcoholic fatty liver disease” in GeneCards (https://www.genecards.org) online database. Thirdly, the intersection of the above two sets was collected to obtain the potential therapeutic target set of FZHY on AFLD through employing the Venny2.1 online tool (https://bioinfogp.cnb.csic.es/tools/venny/index.html). Fourthly, PPI analysis was carried out by the input of the potential therapeutic target set into STRING (https://www.string-db.org/) online database, and KEGG enrichment analysis was carried out by the input of the potential therapeutic target set into DAVID (https://david.ncifcrf.gov/) online database. Finally, the potential therapeutic molecular mechanism and key therapeutic targets of FZHY on AFLD were obtained.

2.2. Materials. The following reagents and instruments were used: absolute ethanol (Sinopharm Chemical Reagent Co., Ltd.), High Sensitivity DNA Kit (Agilent p/n 5067–4626), SuperScript II Reverse Transcriptase with 100 mM DTT and 5X First-Strand Buffer (Invitrogen, 18064014), TruSeq Stranded Total RNA LT Sample Prep Kit 48 Samples (Illumina, 15032612), TruSeq Stranded mRNA LT Sample Prep Kit (Illumina, 15032612), Ribo-Zero rRNA Removal Kits (Epiconcentre, MRZMB126), Agencourt AMPure XP Kit (Beckman p/n A63881), Qubit dsDNA HS Assay Kit (Invitrogen, p/n Q32850), Trizol (Takara), alamine amino transferase (ALT/GPT) test kit (Nanjing Jiancheng Bioengineering Institute, C009-2), triglyceride (TG) test kit (Nanjing Jiancheng Bioengineering Institute, A110-1), Reverse Transcription Kit (Thermo Scientific), qPCR Kit (TaKaRa), SDS-PAGE gel rapid preparation kit (Biorime Biotechnology), PPARα agonist pemafibrate (MedChemExpress), and PPARγ inhibitor GW9662 (MedChemExpress).

2.3. Instruments. Magnetic stand (Invitrogen, k1585-01), 96-well plate (Thermo Fisher, AB0859), MicroCentrifuge (Eppendorf, 5418), centrifuge (Eppendorf, 5424), heat block (BIOER, HB-100), Synergy 2 Microplate Reader (Bio-Tek, Vermont), real-time PCR system (Roche, LightCycler96), and gradient PCR instrument gene amplification instrument (Eppendorf, Mastercycler Nexus Gradient) were used.

2.4. Granules. Artemisia Scopariae Herba granules (Lot no. 18086954), Gardeniae Fructus granules (Lot NO.: 18076664), and Radix Rhei Et Rhizome granules (Lot no. 18096814) were from Jiangyin Tianjiang Pharmaceutical Co., Ltd. In vivo, YCHT recipe stock solution was made by dissolving Artemisia Scopariae Herba granules 80 mg, Gardeniae Fructus granules 40 mg, and Radix Rhei Et Rhizome granules 66 mg in 2 mL normal saline. It was given once daily by gavage at 0.1 mL/10 g. This dose of the YCHT recipe was calculated according to the clinical adult dose. In vitro, 80 mg of Artemisia Scopariae Herba granules, 40 mg of Gardeniae Fructus granules, and 66 mg of Radix Rhei Et Rhizome granules were dissolved in 4 mL of DMEM/F-12 culture medium, filtered by 0.45 mm filters, then divided into EP tube per 35 μL, and stored at −20°C.

2.5. Grouping, AFLD Model Establishment, and Drug Administration. Twenty-four female C57BL/6 mice with an average weight of 20–22 g, purchased from the Experimental Animal Center of the Chinese Academy of Sciences, were raised in the SPF-level breeding room of the Experimental Animal Center of Shanghai University of Traditional Chinese Medicine. Control Lieber–DeCarli liquid diet (TP4030C) and ethanol Lieber–DeCarli liquid diet (TP4030D) were purchased from Trophic Animal Feed High-tech Co., Ltd., Nantong, Jiangsu Province, China. The caloric profile of the diet was shown in Table 1. All mice were randomly divided into three groups (8 mice per group) and were adaptively fed for 5 days with control Lieber–DeCarli liquid diet (TP4030C) which was ethanol-free. After that, mice in the control group were fed with control Lieber–DeCarli liquid diet (TP4030C) daily for 10 days. Mice in the ethanol group were fed with ethanol Lieber–DeCarli liquid diet (TP4030D) containing 5% ethanol daily for 10
days to induce alcoholic fatty liver disease (AFLD). Mice in the YCHT group were fed with ethanol Lieber–DeCarli liquid diet (TP4030D) containing 5% ethanol daily and administered with YCHT recipe stock solution at 0.1 mL/10 g body weight by gavage once a day for 10 days. At the same time, mice in the control and ethanol groups were given normal saline at 0.1 mL/10 g body weight by gavage once a day for 10 days. In the morning of the 11th day, mice in the YCHT and ethanol groups were given a binge dose of 31.5% vol/vol ethanol at 0.2 mL/10 g body weight by gavage after 1 h of the last drug or normal saline administration, and mice in control group were given isocaloric 45% wt/vol maltose dextrin at 0.2 mL/10 g body weight by gavage. 9 h after gavage, all mice were sacrificed. The sera and liver tissues were collected for the following study.

2.6. Serum ALT and TG Measurement. Test operation according to the operating instructions of the kits.

2.7. H&E Staining. Firstly, the paraffin sections of mice liver tissues were baked in an oven at 60°C for 1 to 2 hours and dewaxed with xylene and ethanol. Secondly, hematoxylin was dyed for 10 minutes and washed with running water to remove excess hematoxylin. Thirdly, we put the slices in 0.7% hydrochloric acid ethanol for a few seconds and rinsed with running water, and the slices turned blue for about 15 minutes. Fourthly, the slices were placed in 95% ethanol for 30 seconds and stained with eosin alcohol for 30 seconds. Fifthly, the slices were placed twice in 95% ethanol for 30 seconds and twice in 100% ethanol for 30 seconds. Finally, the slices were placed in xylene for 30 seconds three times and sealed with neutral gum.

2.8. Oil Red Staining. Frozen sections of mice liver tissues were washed with 75% ethanol and stained with Oil Red for 10 minutes. The slices were then placed in 75% ethanol for a few seconds and then washed with pure water. The sections were stained with hematoxylin for 5 minutes and washed with running water. Then, the sections were differentiated with hydrochloric acid and ethanol and rinsed with running water. Finally, glycerol gelatin was used to seal the film.

2.9. RNA-Seq. The total RNA from mice liver tissues of control/ethanol/YCHT groups was extracted by using RNAsio Plus Total RNA extraction reagent and RNeasy Mini Kit according to the standard operating procedures provided by the company. After the Agilent Bioanalyzer 2100 electrophoresis was passed, the total RNA was purified by using the RNAClean XP Kit and the RNase-Free DNase Set. Then, the purified Total RNA was subjected to mRNA isolation, fragmentation, first-strand cDNA synthesis, second-strand cDNA synthesis, terminal repair, 3′ end plus A, ligation, and enrichment, to complete the construction of the sequencing sample library. The library concentration was tested by using a Qubit® 2.0 Fluorometer and the library size was detected by using Agilent 2100. According to the corresponding procedure of the cBot User Guide, the cluster generation and the first-stage sequencing primer hybridization were performed by using the cBot of the Illumina sequencer. The sequencing reagents were provided according to the Illumina User Guide, and the flow cell with the cluster was loaded onto the machine and the paired-end program was used for double-end sequencing. The sequencing was controlled by the data collection software provided by Illumina and real-time data analysis was performed. The library construction and sequencing were performed at Shanghai Biotechnology Corporation, Shanghai, China.

2.10. Data Processing of Transcriptome Sequencing. There are a lot of useless data in the raw reads, such as unqualified data with low overall quality, sequencing primers, and low-end quality. These unqualified data will impact subsequent data analysis and need to be filtered and removed. Sertk screening was used to remove unqualified data. The linker sequence, the 3′ end mass Q below 20 bases, the length less than 25 reads, and ribosome RNA data from the species were all removed. Further analysis was performed by using the screened and removed reads.

2.11. Screening of Differential Expression Genes. The reads are not only proportional to the gene expression level but also related to the length of the gene itself and the amount of data that were sequenced. To obtain comparable data on the gene expression levels of different genes and different samples, the reads were converted into FPKM (fragments per kilobase of exon model per million mapped reads) to standardize the gene expression by three steps which were Stringtie count, TMM (trimmed mean of M values) normalization, and Perl script calculation. Using edgeR to perform differential gene analysis between samples, the p value was obtained, and a multihypothesis test was performed. The threshold of the p-value was determined by controlling the FDR (false discovery rate). The corrected p value was the q value. At the same time, the differential expression multiple was calculated basing on the FPKM value, which was fold change (FC). The screening conditions were $q \leq 0.05$, FC ≥ 2, or FC ≤ 0.5.

### Table 1: Caloric profile of the diet.

|                    | Control diet (TP4030C) | Ethanol diet (TP4030D) |
|--------------------|------------------------|------------------------|
| Protein (kcal per liter) | 180                    | 180                    |
| Fat (kcal per liter)     | 350                    | 350                    |
| Carbohydrate (kcal per liter) | 470                 | 190                    |
| Ethanol (kcal per liter)  | 0                     | 280                    |
| Total (kcal per liter)    | 1,000                 | 1,000                  |
2.12. qRT-PCR. Total RNA extraction and reverse transcription were performed according to the manufacturer's instructions of the kit. The ratio of RNA A260/280 extracted from liver tissue was 1.9–2.0, indicating that the RNA purity was high. Primers designed from the conserved regions of each cDNA were used for quantitative PCR (qPCR) analysis. All primer sequences were listed in Table 2. GAPDH primers were used as the internal control. SYBR green dye was used for qPCR (RR420A, Takara). The relative mRNA expression levels of target genes were calculated by the 2-ΔΔCt method. The amplification parameters were preheating at 95°C for 10 seconds, cycling at 95°C for 5 seconds, and 60°C for 30 seconds for 40 cycles.

2.13. Cell Grouping and Administration. A total of 5 x 10⁴ AML12 hepatocytes per well were grown in 96-well plates, were stimulated by 50 mM alcohol, and cocultured with 11, 33, 100, 300, and 900 μg/mL YCHT for 12h. CCK-8 was used to detect the cytotoxicity of YCHT. The fluorescent staining of Nile Red was used to determine the lipid droplets in cells. From the above experiments, we determined that 300 μg/mL was the optimal concentration for YCHT to reduce hepatocyte steatosis.

Then, a total of 1 x 10⁶ AML12 hepatocytes per well were grown in 6-well plates, stimulated by 50 mM alcohol, and cocultured with 1 μM GW9662 (PPARγ inhibitor) and with or without 300 μg/mL YCHT for 12h. 50 mM alcohol-stimulated AML12 hepatocytes were cocultured with 1 nM pemafibrate (PPARα agonist) and with and without 300 μg/mL YCHT for 3 h. The fluorescent staining of Nile Red was used to determine the lipid droplets in cells. Total RNA was extracted from cells for qRT-PCR.

2.14. Nile Red Staining. Firstly, after AML12 cells were incubated in 96-well plates for 12 hours, the supernatant was discarded, and the cells were washed with 200 μL PBS three times. Secondly, 200 μL 10% formalin was added and the cells were fixed for 2 minutes. Thirdly, formalin was removed. After washing with 200 μL PBS three times, the lipid droplets in cells were stained with 1 μg/mL Nile Red at 37°C for 10 minutes. Fourthly, Nile Red was discarded and the cells were washed with 200 μL PBS three times. Finally, with adding 100 μL PBS, the cells were observed and photographed under a fluorescence microscope, and the data were analyzed by ImageJ software. Relative Fluorescence Units (RFU) = total fluorescence staining intensity of all cells ÷ total fluorescence staining area of all cells.

2.15. Statistics Analysis. Data were presented as means ± SD. Statistical significance was determined by one-way analysis of variance (ANOVA) followed by Bonferroni’s multiple comparisons test by using GraphPad Prism 9.0 software.

3. Results

3.1. PPAR Signaling Pathway Is One of the Important Pathways of Yin-Chen-Hao-Tang (YCHT) in the Treatment of Alcoholic Fatty Liver Disease (AFLD). To explore the potential mechanism and target of YCHT in the prevention and treatment of AFLD, we carried out the network pharmacological analysis.

Through searching the TCMSP database, 41 active ingredients were obtained from Artemisiae Scopariae Herba, 68 active ingredients were obtained from Gardeniae Fructus, and 46 active ingredients were obtained from Radix Rhei Et Rhizome (please refer to the data of column “Mol ID” or “Molecule Name” in Supplementary Materials 1-1, 1-2, and 1-3, respectively, which were the raw data retrieved from the TCMSP database). Finally, 385 potential pharmacological targets of YCHT were obtained by statistical analysis of the corresponding targets of these active components (please refer to the sum data of column “Target Name” from Supplementary Materials 1-1, 1-2, and 1-3, which were the raw data retrieved from the TCMSP database).

The protein-protein interaction (PPI) analysis of 312 potential therapeutic targets was carried out by using the STRING database, and then the PPI data were imported into the software Cytoscape 3.8.0 for further degree value analysis. According to the degree value, the top 30 genes were INS, AKT1, IL6, TP53, CASP3, JUN, EGFR, MYC, STAT3, SRC, MAPK1, MAPK8, MMP9, PTGS2, CXCL8, IL1B, FOS, ESR1, TLR4, CCL2, CCND1, IL10, HSP90AA1, MMP2, CREB1, PPARG, ICAM1, IL4, NOS3, and RELA (please refer to the data of column “Degree” and corresponding column “Name” in Supplementary Material 3, which were the processing results of the Cytoscape 3.8.0 software). Among them, many inflammation-related genes such as IL6, IL1B, TLR4, CCL2, CCND1, IL10, HSP90AA1, MMP2, CREB1, PPARG, ICAM1, IL4, NOS3, and RELA, were included.

The KEGG enrichment analysis of 312 potential therapeutic targets was carried out by using DAVID online database. Inflammation-related pathways, such as the TNF signaling pathway, NF-kappa B signaling pathway, and Toll-like receptor signaling pathway, were obtained, and lipid metabolism-related pathways, such as the adipocytokine signaling pathway and PPAR signaling pathway, were obtained (Figure 1(b)).

3.2. YCHT Improved Ethanol-Induced Liver Injury and Steatosis in Mice. To further illuminate the main targets and signaling pathways of YCHT in the prevention and treatment of AFLD, we established the mouse AFLD model and intervened with YCHT. Serum ALT and HE staining were used to evaluate the level of liver injury, and serum TG and Oil Red staining were used to measure the level of liver steatosis. As shown in Figures 2(b) and 2(c), serum ALT and TG in ethanol-fed mice were markedly increased after ten
days of ethanol feedings ($p < 0.001, p < 0.001$). The livers in ethanol-fed mice exhibited widespread diffuse vesicular steatosis (Figure 2(a), HE staining), a large number of orange-red fat droplets in the cytoplasm (Figures 2(e) and 2(d), Oil Red staining and semi-quantitative), swelling hepatocytes, scattered hepatocyte apoptosis, blurred hepatocyte boundaries, disordered arrangement of hepatic cord, and narrowed hepatic sinusoidal space (Figure 2(a), HE staining). As expected, compared to ethanol-fed mice, serum ALT and TG in the YCHT-administrated mice were significantly decreased ($p < 0.01, p < 0.01$), and the ethanol-induced liver injury and steatosis were obviously improved in the YCHT-administrated mice (Figures 2(a) and 2(b)).

Data in Figures 2(b)–2(d) were all counted by one-way ANOVA followed by Bonferroni’s multiple comparisons test to determine the statistical difference between two groups. Ethanol group versus control group, **** $p < 0.0001$; YCHT group versus ethanol group, ### $p < 0.001$, #### $p < 0.0001$.

### 3.3. Screening the Genes Differentially Expressed in Both YCHT Group (versus Ethanol Group) and Ethanol Group (versus Control Group) Based on RNA-Seq Transcriptomics.

Sifting with $q$ value $\leq 0.05$, FC $\geq 2$, or FC $\leq 0.5$, 1175 differential expression genes were obtained from 17226 genes in ethanol-treated mice compared with control mice, in which 817 genes were upregulated significantly and 358 genes were downregulated significantly (data were shown in the article to be published). 176 differential expression genes were obtained from 17517 genes in YCHT-administered mice compared with ethanol-treated mice, in which 55 genes were upregulated significantly and 121 genes were downregulated significantly (Figure 3). To elucidate the improvement mechanism of YCHT on alcohol-induced liver steatosis and injury, further differential genes screening had been carried out. The set of 176 differential expression genes from YCHT-administered mice compared with ethanol-treated mice was intersected with the set of 1175 differential expression genes from ethanol-treated mice compared with control mice. The screening results showed that the expression of 79 genes was upregulated by ethanol and reversed by YCHT (Table 3). At the same time, the expression of 42 genes was downregulated by ethanol and reversed by YCHT (Table 4). The results suggest that these genes may be related to the effect of YCHT on the alleviation of hepatic steatosis and liver injury.

### 3.4. KEGG Signaling Pathway Enrichment of the Differential Expression Genes.

To discover the key signaling pathway of YCHT in reducing hepatic steatosis and injury, the differential expressed genes in Tables 3 and 4 were further subjected to the DAVID online database for the KEGG signaling pathway enrichment. Enrichment results showed that the "PPAR signaling pathway" ($p < 0.000018$) was the most relevant pathway to the pharmacological effect of YCHT (Table 5). Seven genes, which were PPARγ, CYP7A1, Ehhadh, Cyp4a10, Cyp4a14, Cyp4a31, and Cyp4a32, were found to be distributed in the PPAR signaling pathway (Figure 4).

The gene expression of peroxisome proliferator-activated receptor γ (PPARγ), a transcription factor of fatty acid synthesis-related genes, was increased in the ethanol-fed mice and was decreased in the YCHT-administered mice. The expression of its downstream gene CYP7A1 had the same change tendency (Table 3). These data showed that YCHT could treat alcoholic fatty liver disease by reducing fatty acid and bile acid synthesis. At the same time, the gene expression of peroxisome proliferator-activated receptor α (PPARα), a transcription factor of fatty acid β-oxidation related gene, and its downstream fatty acid oxidation related genes Ehhadh, Cyp4a10, Cyp4a14, Cyp4a31, and Cyp4a32 were all decreased in the ethanol-fed mice and were all increased in the YCHT-administered mice (Table 4, except PPARα gene). Fold change (FC) of the PPARα gene was 0.66 in the ethanol group compared with the control group, and it was FC = 1.58 in the YCHT group compared with the ethanol group (Table 6). Although the FC value of the PPARα gene was out of the screening criteria (FC ≥ 2 or FC ≤ 0.5), its expression trend was consistent with its downstream genes, such as Ehhadh, Cyp4a10, Cyp4a14, Cyp4a31, and Cyp4a32. These data showed that YCHT could also treat alcoholic fatty liver disease by promoting fatty acid oxidation. In brief, the data suggested that the PPAR signaling pathway was the main potential pathway for YCHT to improve alcohol-induced hepatic steatosis in mice.

### 3.5. Verification of RNA-Seq Results by qRT-PCR.

To verify the accuracy of transcriptome analysis, eight genes on the PPAR signaling pathway were selected for quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis. The results showed that the mRNA expression levels of PPAR signaling pathway-related genes verified by
qRT-PCR were basically consistent with the RNA-seq samples, indicating that transcriptome analysis was credible (Figure 5 and Table 6). Data in Figure 5 were all counted by one-way ANOVA followed by Bonferroni’s multiple comparisons test to determine the statistical difference between two groups.
Ethanol group versus control group, \( \ast p < 0.05, \ast\ast p < 0.01, \ast\ast\ast p < 0.001, \ast\ast\ast\ast p < 0.0001 \); YCHT group versus ethanol group, \# p < 0.05, \#\# p < 0.01, \#\#\# p < 0.001, \#\#\#\# p < 0.0001.

3.6. The Effects of YCHT on Protecting from Cell Injury Induced by Alcohol. To investigate the effects of YCHT on cell injury induced by alcohol, the different concentrations of YCHT were used to treat AML12 cells with or without 50 mM alcohol for 12 h, and then cell activity was detected by CCK-8 and the lipid droplets in cells was observed by Nile Red fluorescent staining. It showed that YCHT at a concentration of 900 μg/mL and below had no effect on cell activity and was not cytotoxic (Figure 6(a)). The results of Nile Red fluorescent staining suggested that 300 μg/mL YCHT could obviously reduce the fat production of AML12 hepatocytes stimulated by 50 mM alcohol (Figure 6(b)). Therefore, in the subsequent pharmacological experiments, 300 μg/mL was selected as the experimental concentration of YCHT.

Data in Figures 6(a) and 6(b) were all counted by one-way ANOVA followed by Bonferroni’s multiple comparisons test to determine the statistical difference between two groups. Figure 6(a) shows different concentration YCHT groups versus control group, ns > 0.05. In Figure 6(b), ethanol group versus control group, \ast\ast\ast\ast p < 0.0001; and different concentration YCHT groups versus ethanol group, \#\#\#\# p < 0.0001. Three separate experiments were performed with similar results. Pictures shown were from a single experiment. Data presented were the average of the three independent experiments.

3.7. YCHT Reduces Alcohol-Induced Steatosis of AML12 Hepatocytes by Inhibiting PPARγ Expression and Promoting PPARα Expression. Compared with the normal group, there was no significant difference in intracellular fat production.
in the YCHT, GW9662, and YCHT + GW9662 groups. The fat production in AML12 hepatocytes stimulated by alcohol was significantly increased. Compared with the alcohol group, the fat production in YCHT + alcohol, GW9662 + alcohol, YCHT + GW9662 + alcohol group was significantly reduced, but there was no significant difference among YCHT + alcohol, GW9662 + alcohol, and YCHT + GW9662 + alcohol group (Figure 7(a)).

Compared with the normal group, there was no significant difference in the expression of PPARγ gene mRNA in the YCHT, GW9662, and YCHT + GW9662 group. The relative mRNA expression of the PPARγ gene in the alcohol group was significantly increased and significantly reduced in the YCHT + alcohol group, but there was no significant difference between the YCHT + alcohol and GW9662 + alcohol group (Figure 7(b)). The above results indicated that YCHT could reduce the synthesis of fatty acids and bile acids by inhibiting the PPARγ pathway.

Compared with the normal group, the relative mRNA expression of the PPARα gene has no significant difference among the YCHT, pemafibrate, and YCHT + pemafibrate groups. After alcohol stimulating, the relative mRNA expression of the PPARα gene was significantly reduced, while it increased after YCHT treatment. In addition, with the pemafibrate treatment, the relative mRNA expression of the PPARα gene increased significantly, the same result as in the YCHT + pemafibrate group (Figure 7(c)). The above results indicated that YCHT could improve the oxidative decomposition of fatty acids by promoting the activation of the PPARα pathway.

Data in Figures 7(a)–7(c) were all counted by one-way ANOVA followed by Bonferroni’s multiple comparisons test to determine the statistical difference between two groups. Ethanol group versus control group, \(*\ast \* \ast \ast \ast p < 0.0001\); different concentration YCHT groups versus ethanol group, \(*\ast \ast \ast \ast \ast \ast p < 0.0001\). Three separate experiments were performed with similar results. Pictures shown were from a single experiment. Data presented were the average of the three independent experiments.
4. Discussion

Yin-Chen-Hao-Tang (YCHT) is one of the most famous hepatoprotective herbal formulas in China. YCHT and its modification have been widely used in the clinical treatment of jaundice and various types of liver diseases [10]. It is also used for alcoholic liver disease [4, 5]. YCHT had a good protective effect on serum enzymes and hepatocytes histological changes in acute [11] or chronic [7] rats liver injury induced by ethanol. It could reduce liver fat deposition and resist alcoholic hepatotoxicity in rats [7]. However, the molecular mechanism of YCHT against alcoholic fatty liver disease (AFLD) has not been clarified.

To explore the possible mechanism of YCHT in the prevention and treatment of AFLD, we first conducted a network pharmacological analysis of YCHT. Network pharmacology holds that the process of drugs in vivo is a complex action network, that is, the action process of “multicomponent, multitarget, and multipathway.” Our analysis results show that YCHT can exert the pharmacological effects of preventing and treating AFLD through multiple signal pathways such as inflammation-related pathways and lipid metabolism-related pathways. Inflammation-related pathways include the TNF signaling pathway, NF-kappa B signaling pathway, and Toll-like receptor signaling pathway, and lipid metabolism-related pathways include adipocytokines signaling pathway and PPAR signaling pathway. Because there are many signal pathways involved, we have carried out further research and exploration through experiments in vivo and in vitro, to obtain the most possible signal pathway and target of YCHT in the prevention and treatment of AFLD.

In vivo experiments results showed that YCHT could significantly reduce mice liver injury and hepatic steatosis, and mice liver tissue RNA-seq transcriptome sequencing

Table 3: Fold change of differential expression genes upregulated by ethanol and downregulated by YCHT.

| Gene name          | FC (E/C) | FC (Y/E) | Gene name          | FC (E/C) | FC (Y/E) |
|--------------------|----------|----------|--------------------|----------|----------|
| 4933431E20Rik      | 2.82     | 0.41     | Lmo2               | 2.23     | 0.30     |
| Acot11             | 3.19     | 0.44     | Lrat               | 2.22     | 0.43     |
| Acot6              | 8.04     | 0.36     | Lrtm1              | 5.87     | 0.45     |
| Airm               | 6.64     | 0.28     | Mid1ip1            | 2.31     | 0.23     |
| Aldh3b3            | 2.35     | 0.39     | Mmd2               | 6.52     | 0.31     |
| Apol7a             | 2.09     | 0.49     | Mts1l              | 3.20     | 0.29     |
| Arhgap24           | 2.34     | 0.39     | Myh14              | 9.61     | 0.17     |
| Arrdc4             | 2.90     | 0.39     | Nes                | 2.31     | 0.33     |
| Atp2b2             | 15.34    | 0.24     | Npr3               | 3.61     | 0.40     |
| Calcr1             | 2.02     | 0.39     | Nptx1              | 13.54    | 0.12     |
| Cbr3               | 2.82     | 0.18     | Nr3c2              | 3.43     | 0.46     |
| Cib2               | 2.15     | 0.45     | Pakap              | 10.20    | 0.04     |
| Col15a1            | 11.89    | 0.33     | Phospho1           | 5.30     | 0.43     |
| CYP7a1             | 6.19     | 0.19     | Pparg              | 3.05     | 0.41     |
| Dbp                | 2.43     | 0.34     | Prss8              | 3.46     | 0.37     |
| E030018B13Rik      | 2.37     | 0.32     | Rasgrp3            | 2.08     | 0.39     |
| Esrrg              | 2.46     | 0.40     | Rgs12              | 3.33     | 0.41     |
| Eth1               | 9.94     | 0.47     | Rnf225             | 7.56     | 0.28     |
| Fam198a            | 3.30     | 0.29     | Robo1              | 5.95     | 0.42     |
| Frmd8              | 3.61     | 0.39     | RP23-392K24.6      | 57.54    | 0.13     |
| Gatm               | 2.29     | 0.38     | Samd4              | 7.56     | 0.19     |
| Gbp6               | 2.29     | 0.35     | Sirpa              | 4.87     | 0.34     |
| Gdf10              | 3.65     | 0.48     | Slc15a3            | 3.21     | 0.38     |
| Gdf2               | 2.43     | 0.50     | Slc1a4             | 4.14     | 0.42     |
| Gm12265            | 6.27     | 0.29     | Slc26a1            | 2.42     | 0.49     |
| Gm20521            | 2.30     | 0.50     | Slc26a6            | 2.42     | 0.46     |
| Gm20708            | 12.58    | 0.07     | Slc2a5             | 5.92     | 0.49     |
| Gm35986            | 6.24     | 0.36     | Slc34a2            | 42.56    | 0.13     |
| Gm7694             | 4.15     | 0.39     | Sori1              | 3.26     | 0.39     |
| Gnat1              | 13.64    | 0.37     | Spata2l            | 3.04     | 0.42     |
| Grin3b             | 11.34    | 0.30     | Spsb2              | 2.05     | 0.46     |
| Gstm4              | 8.47     | 0.49     | Srxn1              | 9.75     | 0.41     |
| Hgf                | 2.24     | 0.46     | St6galna4          | 5.63     | 0.34     |
| Hmox1              | 3.01     | 0.32     | Syt12              | 6.25     | 0.30     |
| Iilb               | 3.83     | 0.14     | Tgbrc2             | 5.78     | 0.45     |
| Klf2               | 2.17     | 0.42     | Tnfrsf11b          | 2.60     | 0.45     |
| Klhdc7a            | 13.33    | 0.25     | Tnfsf10            | 2.93     | 0.34     |
| Lgr5               | 2.23     | 0.46     | Tsc22d1            | 3.23     | 0.38     |
| Lhfp1b             | 2.73     | 0.40     | Ttc7               | 2.14     | 0.45     |
| Llilrb             | 3.39     | 0.43     |                    |          |         |

Notes. C: control group; E: ethanol group; Y: YCHT group; FC: fold change.
results showed that the mechanism of YCHT prevention and treatment of AFLD was most related to the PPAR-mediated fatty acid metabolism signaling pathway. Then, we confirmed that YCHT played a pharmacological role in inhibiting hepatocyte steatosis by downregulating PPARγ and upregulating PPARα gene expression through the hepatocyte AFLD model (Figure 8).

The main pathological feature of AFLD is excessive fat accumulation, namely, steatosis, in hepatocytes as a result of increased intracytoplasmic triglyceride formation [12]. PPAR signaling pathway plays an important role in the regulation of hepatic steatosis induced by alcohol [13]. Alcohol can activate the gene expression of PPARγ [14] signaling pathway, which promotes the production of fat, thereby aggravating hepatic steatosis. On the contrary, alcohol can reduce the activity of the PPARα signaling pathway, which decreases the fatty acids (FAs) β-oxidation [15–17], thereby further promoting lipid accumulation in hepatocytes and ultimately leading to hepatic steatosis.

PPARγ, a member of the nuclear hormone receptor superfamily which can regulate the expression of fatty acid synthesis-related genes, participates in lipid metabolism in metabolic tissues, such as liver and skeletal muscle [18]. Ethanol feeding induced liver fat accumulation and mRNA expression of hepatic PPARγ2 in WT mice, which suggests that a high level of PPARγ2 is a common driving force for fat accumulation induced by ethanol [19]. By specific knockout of the PPARγ gene in mouse liver, it was found that alcohol-induced fat accumulation and liver injury in mouse liver were improved [14]. Cholesterol 7α-hydroxylase (CYP7A1) is the rate-limiting enzyme in the classic bile acid synthesis pathway, which plays a critical role in maintaining cholesterol and bile acid homeostasis [20]. PPARγ/CYP7A1 pathway played an important role in the regulation of lipid accumulation and}

| Gene name | FC (E/C) | FC (Y/E) | Gene name | FC (E/C) | FC (Y/E) |
|-----------|----------|----------|-----------|----------|----------|
| 8430408G22Rik | 0.32 | 4.49 | Gm43305 | 0.21 | 2.49 |
| Acot1 | 0.16 | 2.74 | Gm4952 | 0.46 | 2.09 |
| Amotl2 | 0.33 | 2.22 | Hes1 | 0.49 | 2.32 |
| Apc | 0.45 | 2.31 | Il1r1 | 0.16 | 3.74 |
| Arhgef37 | 0.38 | 2.74 | Kpna1 | 0.24 | 4.19 |
| Arntl | 0.32 | 2.25 | Map3k13 | 0.27 | 2.30 |
| Cdkn1a | 0.19 | 2.89 | Nr0b2 | 0.22 | 6.26 |
| Chma2 | 0.32 | 3.02 | Otud1 | 0.33 | 2.11 |
| Clec2h | 0.05 | 11.97 | Pdk4 | 0.07 | 4.34 |
| Clpx | 0.36 | 2.33 | Ptkb1 | 0.41 | 2.14 |
| CYP26a1 | 0.42 | 2.15 | Ppm1k | 0.46 | 2.26 |
| CYP4a10 | 0.30 | 3.23 | Ppp1r3c | 0.41 | 2.18 |
| CYP4a14 | 0.26 | 2.84 | Rnf186 | 0.33 | 2.55 |
| CYP4a31 | 0.28 | 2.37 | Rnf24 | 0.37 | 2.36 |
| CYP4a32 | 0.48 | 2.37 | Scara5 | 0.12 | 8.89 |
| D630039A03Rik | 0.43 | 2.09 | Sgk2 | 0.35 | 2.35 |
| Ehhadh | 0.18 | 2.80 | Slc25a30 | 0.44 | 2.01 |
| Elovl3 | 0.19 | 6.93 | Smad9 | 0.14 | 2.91 |
| Fam107a | 0.05 | 4.84 | Tll8 | 0.20 | 3.09 |
| Fam134b | 0.34 | 2.62 | Upd2 | 0.18 | 2.18 |
| Fkbp5 | 0.42 | 2.08 | Zbfb16 | 0.23 | 3.75 |

**Notes.** C: control group; E: ethanol group; Y: YCHT group; FC: fold change.

| Category | Term | Count | % | p value |
|----------|------|-------|---|---------|
| KEGG PATHWAY | PPAR signaling pathway | 7 | 6 | 0.000018 |
| KEGG PATHWAY | Fatty acid degradation | 5 | 4.3 | 0.00036 |
| KEGG PATHWAY | Retinol metabolism | 6 | 5.2 | 0.00038 |
| KEGG PATHWAY | Inflammatory mediator regulation of TRP channels | 6 | 5.2 | 0.0018 |
| KEGG PATHWAY | Osteoclast differentiation | 6 | 5.2 | 0.0018 |
| KEGG PATHWAY | Arachidonic acid metabolism | 5 | 4.3 | 0.0034 |
| KEGG PATHWAY | Vascular smooth muscle contraction | 5 | 4.3 | 0.012 |
| KEGG PATHWAY | FoxO signaling pathway | 5 | 4.3 | 0.014 |
| KEGG PATHWAY | Transcriptional misregulation in cancer | 5 | 4.3 | 0.028 |
| KEGG PATHWAY | Metabolic pathways | 15 | 12.9 | 0.051 |
| KEGG PATHWAY | Pathways in cancer | 7 | 6 | 0.057 |
| KEGG PATHWAY | Metabolism of xenobiotics by cytochrome P450 | 3 | 2.6 | 0.074 |
| KEGG PATHWAY | Cytokine-cytokine receptor interaction | 5 | 4.3 | 0.089 |
| KEGG PATHWAY | MAPK signaling pathway | 5 | 4.3 | 0.099 |
Figure 4: The enriched genes in the PPAR signaling pathway. Genes in the blue frame represent downregulated genes in the YHCT group compared with the ethanol group, and genes in the red frame represent upregulated genes in the YHCT group compared with the ethanol group.

Table 6: Fold change of gene expression obtained by RNA-seq and qRT-PCR.

| Gene name | Method  | FC (E/C) | FC (Y/E) |
|-----------|---------|----------|----------|
| PPARγ     | RNA-seq | 3.05     | 0.41     |
|           | qRT-PCR | 11.67    | 0.34     |
| CYP7a1    | RNA-seq | 6.19     | 0.19     |
|           | qRT-PCR | 8.88     | 0.16     |
| PPARα     | RNA-seq | 0.66     | 1.58     |
|           | qRT-PCR | 0.47     | 1.6      |
| Ehhadh    | RNA-seq | 0.18     | 2.80     |
|           | qRT-PCR | 0.14     | 4.28     |
| CYP4a10   | RNA-seq | 0.30     | 3.23     |
|           | qRT-PCR | 0.20     | 5.94     |
| CYP4a14   | RNA-seq | 0.26     | 2.84     |
|           | qRT-PCR | 0.24     | 4.47     |
| CYP4a31   | RNA-seq | 0.28     | 2.37     |
|           | qRT-PCR | 0.23     | 4.77     |
| CYP4a32   | RNA-seq | 0.48     | 2.37     |
|           | qRT-PCR | 0.25     | 4.17     |

Notes. C: control group; E: ethanol group; Y: YCHT group; FC: fold change.
cholesterol metabolic transformation in L-02 human hepatic cells [21]. PPARγ overexpression substantially increased the expression of the CYP7A1 gene [22]. Our RNA-seq data showed that alcohol significantly increased the gene expression of PPARγ and CYP7A1, and YCHT markedly inhibited the expression of these two genes (Table 3). These results suggested that YCHT may reduce fatty acid and bile acid synthesis by reducing the gene expression of PPARγ and CYP7A1 and finally improved AFLD. In cell experiments, we discovered that YCHT or GW9662 (PPARγ inhibitor) could, respectively, inhibit PPARγ gene expression and steatosis in ethanol-stimulated hepatocytes. The reduction of ethanol-stimulated hepatocyte steatosis by simultaneous administration of YCHT and GW9662 was almost the same as that of GW9662 alone; YCHT and GW9662 did not show synergistic inhibitory effect on ethanol-stimulated hepatocyte steatosis, indicating that they should play an antisteatosis role through the same signaling pathway. GW9662 alleviated ethanol-stimulated hepatocyte

**Figure 5:** The relative mRNA expression levels of eight PPAR signaling pathway-related genes in mice liver. Results were presented as means ± SD (n = 3 mice/group).
steatosis through inhibiting PPARγ pathway, so YCHT also should exert its anti-ethanol-stimulated hepatocyte steatosis efficacy through PPARγ pathway.

PPARα is also a member of the nuclear hormone receptor superfamily. PPARα can induce the expression of genes involved in the oxidation and transport of free fatty acids, including fatty acid $\beta$-oxidation pathways and membrane transporters, such as carnitine palmitoyltransferase 1 (CPT-1) and apolipoproteins [23]. Enzymes involved in fatty acid oxidation and regulated by PPARα include acetyl-CoA

---

**Figure 6:** Cytotoxicity of YCHT on AML12 hepatocytes and the effect of YCHT on alcohol-induced AML12 hepatocytes steatosis. (a) The effect of different concentrations of YCHT on AML12 hepatocytes activity. (b) The effect of different concentrations of YCHT on the activity and fat production of AML12 hepatocytes stimulated by 50 mM alcohol. Results were presented as means ± SD ($n = 3$ replicates/group).
carboxylase (ACC), fatty acid synthase (FAS), 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoAR), cytochrome p450 4A (Cyp4a), and CPT-1 [24, 25]. Therefore, activation of these enzymes by PPARα agonists can accelerate the degradation of various fatty acids, thus preventing and treating alcoholic liver disease [26]. PPARα activity is positively regulated by NAD-dependent deacetylase sirtuin-1 (SIRT1) in regulating lipid homeostasis. Ethanol-mediated SIRT1
inhibition and SIRT1 dysfunction may cause hyperacetylation of PPARα in the liver. The disturbance of the PPARα signaling pathway will reduce fatty acid oxidation and cause aggravated liver steatosis and inflammation [27]. Our RNA-seq data showed that alcohol could reduce the expression of the PPARα gene and downstream fatty acid oxidation genes Ehhadh, Cyp4a10, Cyp4a14, Cyp4a31, and Cyp4a32. YCHT could increase the expression of these genes (Table 4). In cell experiments, we discovered that YCHT or pemafibrate (PPARα agonist) could, respectively, promote PPARα gene expression in ethanol-stimulated hepatocytes. The increase of PPARα gene expression by simultaneous administration of YCHT and pemafibrate was almost the same as that of pemafibrate alone, and YCHT and pemafibrate did not show synergistic promotion effect on PPARα gene expression, indicating that they might promote PPARα gene expression through the same regulation mechanism. Taken together, these results suggested that YCHT promoted fatty acid oxidation by increasing the expression of PPARα and finally improved AFLD.

5. Conclusions

YCHT reduces the expression of the PPARγ gene, thereby inhibiting lipogenesis in the liver. Meanwhile, YCHT increases the expression of the PPARα gene, thus promoting lipolysis in the liver and finally improving the alcohol-induced hepatic steatosis in mice. In brief, our results indicate that the PPAR signaling pathway is the most important potential targeted pathway for YCHT to improve alcoholic fatty liver disease (AFLD) (Figure 8).

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Ethical Approval

All experimental protocols were approved by the Experimental Animal Welfare and Ethics Committee of Shanghai University of Traditional Chinese Medicine (approval no. PZSHUTCM190712014).

Disclosure

Yi-Wei Zhu, Du Li, and Ting-Jie Ye are the co-first authors.

Conflicts of Interest

All authors declare that they have no conflicts of interest.

Authors’ Contributions

YWZ, DL, FJQ, YLL, and XLW performed the experiments and gave all the data; XDH, YWZ, TJY, XYF, and HL analyzed the data and prepared the figures and tables; YWZ and XDH wrote the manuscript; XDH and XLW conceived and designed the study; XDH and XYF obtained foundation. All authors read and approved the final manuscript. Yi-Wei Zhu, Du Li, and Ting-Jie Ye contributed equally to this work.

Acknowledgments

The authors would like to thank Research Square (https://www.researchsquare.com/article/rs-818720/v1) for publishing their manuscript’s preprint on September 13, 2021 [28]. This study was supported by the Teachers’ Academic Community Project of Shanghai University of Traditional
Chinese Medicine (P304030105), Scientific Research Project within the Budget of Shanghai University of Traditional Chinese Medicine (2020LK002), and the National Natural Science Foundation of China (no. 81703832).

Supplementary Materials

Supplementary Material 1-1: Herb Target-Artemisiae Scopariae Herba. Supplementary Material 1-2: Herb Target-Gardeniae Fructus. Supplementary Material 1-3: Herb Target-Radix Rhei Et Rhizome. Supplementary Material 2: AFLD-GeneCards-SearchResults. Supplementary Material 3: string_interactions.tsv default node. (Supplementary Materials)

References

[1] J. Rehm, A. V. Samokhvalov, and K. D. Shield, “Global burden of alcoholic liver diseases,” *Journal of Hepatology*, vol. 59, no. 1, pp. 160–168, 2013.

[2] W.-J. Wang, P. Xiao, H.-Q. Xu, J.-Q. Niu, and Y.-H. Gao, “Growing burden of alcoholic liver disease in China: a review,” *World Journal of Gastroenterology*, vol. 25, no. 12, pp. 1445–1456, 2019.

[3] J. Liu, “Ethanol and liver: recent insights into the mechanisms of ethanol-induced fatty liver,” *World Journal of Gastroenterology*, vol. 20, no. 40, pp. 14672–14685, 2014.

[4] L. Ma and J. M. Ma, “Clinical observation of Yin-Chen-Hao-Tang in the treatment of alcoholic liver disease,” *Ningxia Medical Journal*, vol. 31, no. 10, pp. 923–924, 2009.

[5] S. Y. Wang and Y. J. Wang, “Yin-Chen-Hao-Tang and Chai-Hu-Shu-Gan-San in the treatment of AFLD 46 cases,” *Asia-Pacific Traditional Medicine*, vol. 22, no. 5, pp. 54–55, 2007.

[6] L. Wang, H. J. Wang, K. Wu, and D. Q. Hu, “Effect of Yinchenhao decoction on both hepatic and intestinal histopathology in rats with alcoholic liver disease,” *Global Chinese Medicine*, vol. 8, no. 11, pp. 1329–1332, 2015.

[7] M. X. Huang, Q. Wu, and J. Y. Pan, “Effects of Yin-Chen-Hao-Tang on liver protection, anti-free radical damage and blood lipid lowering in rats with alcoholic-induced fatty liver,” *Strait Pharmaceutical Journal*, vol. 27, no. 2, pp. 21–24, 2015.

[8] Y. X. Gu, Q. Wu, S. J. Chen, L. J. Chen, J. Q. Pan, and L. Y. Xiao, “Effect of Yin-Chen-Hao-Tang on alcoholic fatty liver disease in rats,” *China New Medicine*, vol. 3, no. 7, pp. 17–19, 2004.

[9] B. G. Zhou, S. R. Yu, S. L. Gao, and S. Zhen, “Protective effect of Jiawei Yinchenhao Decoction on acute alcoholic liver injury in mice,” *Lishizhen Medicine and Materia Medica Research*, vol. 23, no. 7, pp. 1720–1722, 2012.

[10] J.-Y. Li, H.-Y. Cao, L. Sun et al., “Therapeutic mechanism of Yin-Chen-Hao decoction in hepatic diseases,” *World Journal of Gastroenterology*, vol. 23, no. 7, pp. 1125–1138, 2017.

[11] L. Liu, H. Sun, and X. J. Wang, “Hepatoprotection of Yin Chen Hao Tang on acute rat liver injury induced by ethanol,” *Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology*, vol. 9, no. 4, pp. 35–40, 2007.

[12] F. A. Livero and A. Acco, “Molecular basis of alcoholic fatty liver disease: from incidence to treatment,” *Hepatology Research: The Official Journal of the Japan Society of Hepatology*, vol. 46, no. 1, pp. 111–123, 2016.

[13] K. Ohashi, M. Pimienta, and E. Seki, “Alcoholic liver disease: a current molecular and clinical perspective,” *Liver Research*, vol. 2, no. 4, pp. 161–172, 2018.

[14] W. Zhang, Q. Sun, W. Zhong, X. Sun, and Z. Zhou, “Hepatic peroxisome proliferator-activated receptor gamma signaling contributes to alcohol-induced hepatic steatosis and inflammation in mice,” *Alcoholism: Clinical and Experimental Research*, vol. 40, no. 5, pp. 988–999, 2016.

[15] T. Nakajima, Y. Kamijo, N. Tanaka et al., “Peroxisome proliferator-activated receptor? Protects against alcohol-induced liver damage,” *Hepatology*, vol. 40, no. 4, pp. 972–980, 2004.

[16] M. You, X. Liang, J. M. Ajmo, and G. C. Ness, “Involvement of mammalian sirtuin 1 in the action of ethanol in the liver,” *American Journal of Physiology - Gastrointestinal and Liver Physiology*, vol. 294, no. 4, pp. G892–G898, 2008.

[17] D. W. Crabb and S. Liangpunsakul, “Alcohol and lipid metabolism,” *Journal of Gastroenterology and Hepatology*, suppl. no. 3, pp. S56–S60, 2006.

[18] A. Vidal-Puig, M. Jimenez-Liñan, B. B. Lowell et al., “Regulation of PPAR gamma gene expression by nutrition and obesity in rodents,” *Journal of Clinical Investigation*, vol. 97, no. 11, pp. 2553–2561, 1996.

[19] J. E. Park, M. Lee, R. Mifflin, and Y. K. Lee, “Enhanced ethanol catabolism in orphan nuclear receptor SHP-null mice,” *American Journal of Physiology-Gastrointestinal and Liver Physiology*, vol. 310, no. 10, pp. G799–G807, 2016.

[20] J. Y. L. Chiang, “Bile acids: regulation of synthesis,” *Journal of Lipid Research*, vol. 50, no. 10, pp. 1955–1966, 2009.

[21] O. Lv, L. Wang, J. Li, Q. Ma, and W. Zhao, “Effects of pomegranate peel polyphenols on lipid accumulation and cholesterol metabolic transformation in L-02 human hepatic cells via the PPARy-ABCA1/CYP7A1 pathway,” *Food & Function*, vol. 7, no. 12, pp. 4976–4983, 2016.

[22] T. Han, Y. Lv, S. Wang, T. Hu, H. Hong, and Z. Fu, “γPPARγ overexpression regulates cholesterol metabolism in human L02 hepatocytes,” *Journal of Pharmacological Sciences*, vol. 139, no. 1, pp. 1–8, 2019.

[23] Y. Songtao, R. Sambasiva, and J. K. Reddy, “Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis,” *Current Molecular Medicine*, vol. 3, no. 6, pp. 561–572, 2003.

[24] J. P. Hardwick, “Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases,” *Biochemical Pharmacology*, vol. 75, no. 12, pp. 2263–2275, 2008.

[25] D. D. Patel, B. L. Knight, D. Wiggins, S. M. Humphreys, and G. F. Gibbons, “αDisturbances in the normal regulation of SREBP-sensitive genes in PPARα-deficient mice,” *Journal of Lipid Research*, vol. 42, no. 3, pp. 328–337, 2001.

[26] V. Purohit, B. Gao, and B. J. Song, “Molecular mechanisms of alcoholic fatty liver disease,” *Alcoholism: Clinical and Experimental Research*, vol. 33, no. 2, pp. 191–205, 2010.

[27] M. You, A. Jogasuria, C. Taylor, and J. Wu, “Sirtuin 1 signaling and alcoholic fatty liver disease,” *Hepatobiliary Surgery and Nutrition*, vol. 4, no. 2, pp. 88–100, 2015.

[28] Y.-W. Zhu, D. Li, T.-J. Ye et al., “The study of yin-chen-hao-tang preventing and treating alcoholic fatty liver disease through PPAR signaling pathway based on network pharmacology and RNA-seq transcriptomics,” *Research Square*, 2021.